University of Michigan at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Michigan brings 2 presentations to ASH 2026 in New Orleans. Its program spans bispecific antibodies for lymphoma, individualized hemophilia care and inherited hemolytic anemias. It also covers better clinical endpoints for sickle cell disease, seen from several disciplines.
| Organization | ASH 2026 Attendance |
|---|---|
University of Michigan Ann Arbor, MI | |
Public research university in Ann Arbor with the Michigan Medicine academic medical center. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 3:00pm–6:00pm Hemophilia at the Crossroads: New Evidence for Individualized Care Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden. Talk Management Considerations in Inherited Hemolytic Anemias How genetic testing is replacing stepwise diagnosis of inherited hemolytic anemias, with pyruvate kinase deficiency and mitapivat as a model of targeted therapy. |
Instantly find 20 buyers from University of Michigan
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction